Daiichi Sankyo Company (4568) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
8 May, 2026FY2025 Financial Forecast Revision
Operating profit forecast reduced by JPY 106 billion to JPY 229 billion due to temporary expenses, including JPY 75.7 billion for CMO compensation and JPY 19.3 billion for canceled ADC CapEx at Odawara.
Revenue forecast for FY2025 increased by JPY 23 billion to JPY 2,123 billion, while profit attributable to owners is expected at JPY 260 billion.
Cost of sales decreased by JPY 19 billion, but SG&A expenses rose by JPY 31 billion and R&D expenses by JPY 2 billion.
Temporary expenses stem from revised supply plans, minimum purchase obligations with CMOs, and impairment losses from canceled investments.
Exchange rates updated to USD/JPY 150.78 and EUR/JPY 174.79.
ADC Manufacturing and Supply Strategy Update
Initial ADC supply relied on both in-house and CMO manufacturing, with phased capacity expansion and a focus on stable supply.
Market demand for ADCs exceeded initial plans, prompting a shift to a hybrid model with expanded CMO utilization and long-term commitments.
New supply plan incorporates risk adjustments, leading to lower cumulative volumes and discrepancies with minimum purchase obligations.
Strategic shift aims to optimize roles between in-house and CMO manufacturing, leveraging flexibility and transferring established technologies for commercial production.
Ongoing discussions with CMOs include flexible use of manufacturing capacity and possible transfers to third parties.
Financial and Dividend Policy Outlook
Temporary expenses for CMO compensation are recorded for the short term; future provisions may arise depending on demand and clinical outcomes.
Annual dividend forecast for FY2025 remains at JPY 78 per share, with plans to continue increasing dividends in line with the established five-year business plan.
CapEx for in-house manufacturing will be more selective, focusing on necessary and maintenance investments, with further details to be disclosed in the upcoming five-year business plan.
Initiatives are underway to minimize actual losses related to CMO compensation fees.
Latest events from Daiichi Sankyo Company
- Oncology-led growth and rising dividends drive ambitious 2030 targets despite one-time costs.4568
Q4 202611 May 2026 - FY2024 profit and revenue surged on oncology growth; FY2025 targets higher dividends and R&D.4568
Q4 202518 Feb 2026 - Oncology-driven revenue and core profit growth, with stable guidance and higher temporary costs.4568
Q3 202618 Feb 2026 - I-DXd achieved 48.2% ORR and durable benefit in relapsed ES-SCLC, with Phase 3 trials ongoing.4568
Status Update3 Feb 2026 - T-DXd delivers strong PFS and ORR gains in HER2-low/ultralow mBC, broadening patient reach.4568
Status Update31 Jan 2026 - Oncology-driven sales and FX gains fueled profit growth and a raised FY2024 outlook.4568
Q2 202517 Jan 2026 - ADC innovation and global expansion drive strong growth and top 10 oncology ambitions.4568
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - DXd ADCs achieve clinical, regulatory, and supply milestones, expanding global impact.4568
Status Update11 Jan 2026 - Sustainability, diversity, and innovation drive growth, with strong ESG and governance progress.4568
Status Update10 Jan 2026